GlobeNewswire

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
04/11/2026
– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide – – [...]
Medline Reports Third Quarter and Nine Months 2026 Results
04/11/2026
Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.8% Nine months net sales of $ [...]
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
04/11/2026
- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + [...]
Kane Announces Publication of Real-World Evidence in the International Wound Journal
04/11/2026
Study reports improvements across multiple wound-healing outcomes associated with adjunctive use of revyve® Antimicrobial Wound Gel WINNIPEG, Manitoba, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ( [...]
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
04/11/2026
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S. [...]
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
04/11/2026
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract [...]
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
04/11/2026
Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million [...]
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
04/11/2026
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step [...]
AC Immune Third Quarter 2026 Financial and Corporate Update
04/11/2026
AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) [...]
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
04/11/2026
Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds Radiopharm Theranostics [...]
Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets
04/11/2026
Non-systemic, pre-meal chewable nutraceutical designed to help blunt post-meal blood sugar spikes enters a region where roughly 7.5 million adults in the UAE, Saudi Arabia and Kuwait are living with diabetes Boston, MA [...]
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
04/11/2026
Updated data to be presented at SITC 2026; Company to host key opinion leaders webinar on November 10 TORONTO and HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ( [...]
Sironax Announces Two Abstracts on NAMPT Activator SIR4156 Selected for Presentation at ObesityWeek 2026
04/11/2026
Obesity Society annual meeting, November 14-17 Gaylord National Resort & Convention Center, National Harbor, MD WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology [...]
Repligen Corporation to Present at Jefferies Global Healthcare Conference
04/11/2026
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and [...]
Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026
04/11/2026
BANNOCKBURN, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
04/11/2026
BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced [...]
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
04/11/2026
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
04/11/2026
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company’s lead [...]
BioCryst Reports Third Quarter 2026 Financial Results
04/11/2026
— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum